Iph4102-201

Author: uhoc

August undefined, 2024

WebClinical Trial Name: IPH4102-201 / TELLOMAK study Clinical Trial Description: The trial is an open label, multi-cohort and multi-center phase II. It is designed to include a total of 3 … Web29 jan. 2024 · IPH4102 is Innate Pharma’s wholly-owned first-in-class anti-KIR3DL2 antibody, developed for the treatment of T-cell lymphoma. Fast Track is a process designed to facilitate the development and expedite the regulatory review of investigational drugs to treat serious conditions and fill an unmet medical need.

INNATE PHARMA: Preliminary safety and clinical activity

Web26 okt. 2016 · IPH4102 is Innate Pharma's wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. date and time language

IPH4102 on Cutaneous T-Cell Lymphoma - Clinical Trials Registry

Web14 mrt. 2024 · Biological: IPH4102 Study Type Interventional Enrollment (Anticipated) 166 Phase Phase 2 Contacts and Locations This section provides the contact details for … WebInnate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the design of the “TELLOMAK” Phase II trial and new preclinical data supporting the potential of IPH4102 in peripheral T-cell lymphoma (“PTCL”) as well as Adult T-cell leukemia/lymphoma (“ATLL”) will be presented at the International Conference on … Web• Initiation of IPH4102 , an international, openTELLOMAK -label, multicohort Phase II - study evaluating the efficacy and safety of IPH4102 in patient populations larger expressing KIR3DL2, including peripheral T cell lymphoma (PTCL). TELLOMAK is planned to recruit up to 250 patients, with IPH4102 evaluated as a single agent in bitwig layered editing

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in …

WebIPH4102 alleen of in combinatie met chemotherapie bij patiënten met gevorderd T-cellymfoom TELLOMAK: T-cellymfoom Anti-KIR3DL2-therapie. Een open label, … Web12 jun. 2024 · IPH4102 is a humanized first-in-class anti-KIR3DL2 monoclonal antibody designed to deplete KIR3DL2-expressing cells via antibody-dependent cell-cytotoxicity (ADCC) and phagocytosis. bitwig launcher clip editingWebThe EU Clinical Trials Register currently displays 43281 clinical trials with a EudraCT protocol, of which 7159 are clinical trials conducted with subjects less than 18 years old. … bitwig live performance

"WebSézary syndrome (SS), the most aggressive form of cutaneous T-cell lymphoma (CTCL), is characterized by a high expression of the KIR3DL2 receptor. Speaking f... " - Iph4102-201

Iph4102-201

Innate Pharma begins enrolment in TELLOMAK clinical trial

WebProtocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma Zhou, A. Medpace Clinical Research LLC, Innate Pharma SA 4/12/22 → 4/12/25 Project: Research project WebStudy of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma. A.4.1 Sponsor's protocol code number IPH4102-201 A.5.2 US NCT …

Did you know?

Web12 apr. 2024 · Protocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with … WebAn open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma. 2024-003969-33 Databank klinische proeven

Web13 sep. 2024 · IPH4102 in PTCL were presented at 2024 International Conference on the Malignant Lymphoma (ICML) in June 2024. o The outcome of the first stage of the MF and PTCL cohorts is expected in the second half of 2024. Initial efficacy data are expected starting in 2024. o Study results from the Phase I dose-escalation and expansion trial of … Web3 apr. 2024 · IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. … IPH4102 Alone or in Combination With Chemotherapy in Patients With …

Web15 jun. 2024 · About IPH4102: IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T... WebInterpretation IPH4102 is safe and shows encouraging clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome. If confirmed in future trials, IPH4102 could become a novel treatment option for these patients. A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm

Web6 dec. 2024 · In this trial, IPH4102 is evaluated alone and in combination with chemotherapy in patients with advanced TCL. TELLOMAK is expected to recruit up to 250 patients, with …

WebIPH4102-201: National Competent Authority: Italy - Italian Medicines Agency: Clinical Trial Type: EEA CTA: Trial Status: Ongoing: Date on which this record was first entered in the … date and time is wrong on windowsWeb25 jun. 2024 · IPH4102 is a humanised, first-in-class, monoclonal antibody that targets KIR3DL2, a cell surface protein widely expressed in cutaneous T-cell lymphoma, and … date and time jfk was assassinatedWeb28 sep. 2024 · De 29 ste (a.s.zaterdag) dus de presentatie en updates van Innate Pharma Januari 2024 nog 15,57 . De pipeline staat nu een stuk verder in ontwikkeling . De koers niet EORTC CLTF 2024 MEETING CUTANEOUS LYMPHOMA ST GALLEN, SWITZERLAND September 27, 2024 to September 29, 2024 Updated data from ongoing clinical trial … date and time is wrongWeb3 dec. 2024 · innate pharma announces updated results that support advancement of iph4102 in refractory sÉzary syndrome at the american society of hematology 2024 annual meeting differentiating... march 26, 2024 date and time language changeWeb7 jun. 2024 · IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody that depletes KIR3DL2-expressing cells through antibody-dependent cell-cytotoxicity and … bitwig max for liveWeb12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der … bitwig locationsWeb1 jun. 2024 · Background IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form,... bitwig midi output routing